Levofloxacin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (3)Enzymes (2)Transporters (4)

Targets (3)Enzymes (2)Transporters (4)Biointeractions (10)

Identification

Name

Levofloxacin

Accession Number

DB01137 (APRD00477, DB06085)

Type

Small Molecule

Groups

Approved, Investigational

Description

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(-)-Ofloxacin

(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid

(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid

(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid

(S)-Ofloxacin

L-ofloxacin

Levofloxacine

Levofloxacino

Levofloxacinum

Ofloxacin S-(-)-form

External IDs

MP-376

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Levofloxacin hemihydrate	6GNT3Y5LMF	138199-71-0	SUIQUYDRLGGZOL-RCWTXCDDSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Levofloxacin	Tablet	750 mg	Oral	Actavis Pharma Company	2009-06-24	Not applicable	Canada
Act Levofloxacin	Tablet	250 mg	Oral	Actavis Pharma Company	2009-06-24	Not applicable	Canada
Act Levofloxacin	Tablet	500 mg	Oral	Actavis Pharma Company	2009-06-24	Not applicable	Canada
Auro-levofloxacin	Tablet	500 mg	Oral	Auro Pharma Inc	2016-04-12	Not applicable	Canada
Auro-levofloxacin	Tablet	750 mg	Oral	Auro Pharma Inc	2016-04-12	Not applicable	Canada
Auro-levofloxacin	Tablet	250 mg	Oral	Auro Pharma Inc	2016-04-12	Not applicable	Canada
Ava-levofloxacin	Tablet	250 mg	Oral	Avanstra Inc	2011-09-15	2014-08-21	Canada
Ava-levofloxacin	Tablet	500 mg	Oral	Avanstra Inc	2011-09-15	2014-08-21	Canada
Dom-levofloxacin	Tablet	500 mg	Oral	Dominion Pharmacal	Not applicable	Not applicable	Canada
Dom-levofloxacin	Tablet	750 mg	Oral	Dominion Pharmacal	Not applicable	Not applicable	Canada
Dom-levofloxacin	Tablet	250 mg	Oral	Dominion Pharmacal	Not applicable	Not applicable	Canada
Iquix	Solution	15 mg/mL	Ophthalmic	Vistakon Pharmaceuticals	2004-06-01	Not applicable	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Physicians Total Care, Inc.	2005-08-02	Not applicable	US
Levaquin	Injection, solution	5 mg/mL	Intravenous	Janssen Pharmaceuticals	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	A S Medication Solutions	1996-12-20	2017-06-20	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Rebel Distributors	1996-12-20	Not applicable	US
Levaquin	Injection, solution	5 mg/mL	Intravenous	Janssen Pharmaceuticals	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Red Pharm Drug, Inc.	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Remedy Repack	2013-04-10	2016-10-13	US
Levaquin	Tablet, film coated	250 mg/1	Oral	Cardinal Health	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Janssen Pharmaceuticals	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Physicians Total Care, Inc.	2000-05-11	Not applicable	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Rebel Distributors	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Cardinal Health	1996-12-20	Not applicable	US
Levaquin	Solution	25 mg/mL	Oral	Janssen Pharmaceuticals	2004-10-21	Not applicable	US
Levaquin	Tablet	250 mg	Oral	Janssen Pharmaceuticals	1997-11-28	2014-10-27	Canada
Levaquin	Solution	25 mg/mL	Oral	Patriot Pharmaceuticals	2013-07-01	2016-12-07	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	2017-05-09	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	250 mg/1	Oral	Red Pharm Drug, Inc.	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	250 mg/1	Oral	Remedy Repack	2013-04-11	2016-10-13	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Janssen Pharmaceuticals	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	250 mg/1	Oral	Physicians Total Care, Inc.	2000-05-12	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	bryant ranch prepack	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Red Pharm Drug, Inc.	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Cardinal Health	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	250 mg/1	Oral	Janssen Pharmaceuticals	1996-12-20	Not applicable	US
Levaquin	Injection, solution	5 mg/mL	Intravenous	Janssen Pharmaceuticals	1996-12-20	Not applicable	US
Levaquin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	2016-05-26	2017-03-11	US
Levaquin	Tablet, film coated	500 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-01-27	Not applicable	US
Levaquin 25mg/ml	Solution	25 mg	Intravenous	Janssen Pharmaceuticals	1998-01-29	2006-08-04	Canada
Levaquin 500mg	Tablet	500 mg	Oral	Janssen Pharmaceuticals	1997-11-28	2015-04-02	Canada
Levaquin 5mg/ml	Solution	5 mg	Intravenous	Janssen Pharmaceuticals	1997-11-28	2014-03-19	Canada
Levaquin 750mg	Tablet	750 mg	Oral	Janssen Pharmaceuticals	2004-01-30	2015-03-27	Canada
Levofloxacin	Tablet	250 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Levofloxacin	Tablet	500 mg	Oral	Pro Doc Limitee	2013-11-28	Not applicable	Canada
Levofloxacin	Tablet	500 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Levofloxacin	Tablet	750 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Levofloxacin In 5% Dextrose Injection	Solution	5 mg	Intravenous	Hospira, Inc.	2011-12-23	Not applicable	Canada
Levofloxacin In 5% Dextrose Injection	Solution	5 mg	Intravenous	Sterimax Inc	Not applicable	Not applicable	Canada
Levofloxacin Injection	Solution	5 mg	Intravenous	Teva	Not applicable	Not applicable	Canada
Mylan-levofloxacin	Tablet	250 mg	Oral	Mylan Pharmaceuticals	2009-06-24	Not applicable	Canada
Mylan-levofloxacin	Tablet	500 mg	Oral	Mylan Pharmaceuticals	2009-06-24	Not applicable	Canada
Ntp-levofloxacin	Tablet	500 mg	Oral	Teva	Not applicable	Not applicable	Canada
Ntp-levofloxacin	Tablet	750 mg	Oral	Teva	Not applicable	Not applicable	Canada
Ntp-levofloxacin	Tablet	250 mg	Oral	Teva	Not applicable	Not applicable	Canada
PHL-levofloxacin	Tablet	250 mg	Oral	Pharmel Inc	Not applicable	Not applicable	Canada
PHL-levofloxacin	Tablet	750 mg	Oral	Pharmel Inc	Not applicable	Not applicable	Canada
PHL-levofloxacin	Tablet	500 mg	Oral	Pharmel Inc	Not applicable	Not applicable	Canada
PMS-levofloxacin	Tablet	750 mg	Oral	Pharmascience Inc	2009-06-24	Not applicable	Canada
PMS-levofloxacin	Tablet	500 mg	Oral	Pharmascience Inc	2009-06-24	Not applicable	Canada
PMS-levofloxacin	Tablet	250 mg	Oral	Pharmascience Inc	2009-06-24	Not applicable	Canada
Quinsair	Solution	240 mg	Respiratory (inhalation)	Horizon Pharma, Inc.	2016-12-12	Not applicable	Canada
Quixin	Solution	5 mg/mL	Ophthalmic	Vistakon Pharmaceuticals	2000-10-01	Not applicable	US
Sandoz Levofloxacin	Tablet	750 mg	Oral	Sandoz Canada Incorporated	2009-06-24	Not applicable	Canada
Sandoz Levofloxacin	Tablet	250 mg	Oral	Sandoz Canada Incorporated	2009-06-24	Not applicable	Canada
Sandoz Levofloxacin	Tablet	500 mg	Oral	Sandoz Canada Incorporated	2009-06-24	Not applicable	Canada
Teva-levofloxacin	Tablet	500 mg	Oral	Teva	2004-11-30	Not applicable	Canada
Teva-levofloxacin	Tablet	250 mg	Oral	Teva	2004-11-30	Not applicable	Canada
Teva-levofloxacin	Tablet	750 mg	Oral	Teva	2009-06-24	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-levofloxacin	Tablet	500 mg	Oral	Apotex Corporation	2009-06-24	Not applicable	Canada
Apo-levofloxacin	Tablet	750 mg	Oral	Apotex Corporation	2009-06-24	Not applicable	Canada
Apo-levofloxacin	Tablet	250 mg	Oral	Apotex Corporation	2009-06-24	Not applicable	Canada
Levaquin	Tablet	250 mg/1	Oral	Directrx	2016-05-26	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Sagent Pharmaceuticals	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Torrent Pharmaceuticals Limited	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Remedy Repack	2013-12-31	2017-07-20	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Sandoz	2011-07-07	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2012-03-30	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Av Kare, Inc.	2013-07-12	2016-10-13	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Lupin Pharmaceuticals	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	Not applicable	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Lucid Pharma Llc	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Blenheim Pharmacal, Inc.	2015-03-26	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Red Pharm Drug, Inc.	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Northwind Pharmaceuticals	2015-05-14	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Dr Reddy's Laboratories	2011-06-20	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Aidarex Pharmaceuticals LLC	2012-03-30	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Citron Pharma LLC	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Red Pharm Drug, Inc.	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Directrx	2015-01-01	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Hospira, Inc.	2015-09-03	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-06-21	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Boca Pharmacal, Inc.	2012-08-17	2017-02-18	US
Levofloxacin	Tablet	250 mg/1	Oral	A S Medication Solutions	2012-03-30	2017-06-20	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Mesource Pharmaceuticals	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Red Pharm Drug, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	bryant ranch prepack	2011-06-20	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	Cardinal Health	2011-06-23	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-02-04	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2012-12-02	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	2016-04-14	2016-10-26	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	bryant ranch prepack	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Macleods Pharmaceuticals Limited	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Teva	2011-06-20	2016-05-31	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Amerincan Health Packaging	2011-07-01	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Cardinal Health	2013-12-01	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Major	2013-12-01	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Remedy Repack	2016-01-07	2017-04-14	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Red Pharm Drug, Inc.	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Red Pharm Drug, Inc.	2015-01-09	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Wockhardt	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Directrx	2015-01-01	Not applicable	US
Levofloxacin	Injection, solution	250 mg/50mL	Intravenous	West Ward Pharmaceutical	2011-09-16	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Boca Pharmacal, Inc.	2012-08-17	2017-02-18	US
Levofloxacin	Injection, solution	25 mg/mL	Intravenous	Claris Lifesciences, Inc.	2013-07-01	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	West Ward Pharmaceutical	2011-06-21	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2011-06-20	2017-01-14	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	2015-04-29	2017-04-14	US
Levofloxacin	Injection, solution	750 mg/150mL	Intravenous	Auro Medics Pharma Llc	2016-02-10	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-09-05	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Proficient Rx LP	2012-03-30	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	WG Critical Care, LLC	2016-04-14	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Aidarex Pharmaceuticals LLC	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Camber Pharmaceuticals	2015-01-09	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-11-14	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Rebel Distributors	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Cardinal Health	2013-12-01	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Major	2011-06-23	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2012-11-10	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	A S Medication Solutions	2012-03-30	2017-06-20	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	A S Medication Solutions	2012-08-17	2017-06-20	US
Levofloxacin	Tablet	500 mg/1	Oral	Torrent Pharmaceuticals Limited	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Physicians Total Care, Inc.	2011-09-15	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	New Horizon Rx Group, LLC	2013-08-25	Not applicable	US
Levofloxacin	Injection, solution, concentrate	25 mg/mL	Intravenous	Sagent Pharmaceuticals	2012-01-05	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Proficient Rx LP	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	A S Medication Solutions	2012-11-10	2017-06-20	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Av Kare, Inc.	2013-07-12	2016-10-13	US
Levofloxacin	Tablet	750 mg/1	Oral	Wockhardt	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-01-09	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Unit Dose Services	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Red Pharm Drug, Inc.	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-06-20	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Aidarex Pharmaceuticals LLC	2011-06-20	Not applicable	US
Levofloxacin	Solution / drops	5 mg/mL	Topical	Rising Pharmaceuticals	2010-12-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Red Pharm Drug, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Red Pharm Drug, Inc.	2011-06-20	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Cardinal Health	2011-06-23	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Hikma Pharmaceutical	2011-06-21	Not applicable	US
Levofloxacin	Injection	5 mg/mL	Intravenous	Fresenius Kabi	2013-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Cadila Pharnmaceuticals	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Proficient Rx LP	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Sandoz	2011-06-20	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Claris Lifesciences, Inc.	2013-07-01	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Sandoz	2011-07-07	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Aurobindo Pharma	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-11-13	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	Cipla Limited	2012-03-30	Not applicable	US
Levofloxacin	Injection, solution	250 mg/50mL	Intravenous	Auro Medics Pharma Llc	2016-02-10	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Major	2013-12-01	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	2016-08-15	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	WG Critical Care, LLC	2016-04-14	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	A S Medication Solutions	2012-08-17	2017-06-20	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Camber Pharmaceuticals	2015-01-09	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2011-08-12	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Stat Rx USA	2011-08-13	Not applicable	US
Levofloxacin	Injection, solution, concentrate	500 mg/20mL	Intravenous	Auro Medics Pharma Llc	2013-01-24	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	Major	2011-06-23	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Boca Pharmacal, Inc.	2012-08-17	2018-09-28	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-06-20	2016-12-21	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Lupin Pharmaceuticals	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2017-04-04	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Lucid Pharma Llc	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Apotheca, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Nu Care Pharmaceuticals ,Inc.	2012-03-30	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Northwind Pharmaceuticals	2014-03-03	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Dr Reddy's Laboratories	2011-06-20	Not applicable	US
Levofloxacin	Injection	25 mg/mL	Intravenous	Heritage	2013-02-04	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Citron Pharma LLC	2011-06-20	Not applicable	US
Levofloxacin	Injection	25 mg/mL	Intravenous	Akorn	2011-07-01	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Proficient Rx	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Apotheca, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-06-20	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	Wockhardt	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Solution / drops	5 mg/mL	Ophthalmic	Hi Tech Pharmacal Co., Inc.	2011-02-10	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Red Pharm Drug, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Red Pharm Drug, Inc.	2012-03-30	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	Wockhardt	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	H.J. Harkins Company	2011-11-22	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Directrx	2015-01-01	Not applicable	US
Levofloxacin	Injection, solution	750 mg/150mL	Intravenous	West Ward Pharmaceutical	2011-09-16	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	bryant ranch prepack	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Macleods Pharmaceuticals Limited	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Teva	2011-06-20	2016-06-30	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Amerincan Health Packaging	2011-07-01	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Cardinal Health	2013-12-01	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Proficient Rx LP	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Cadila Pharnmaceuticals	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Sandoz	2011-06-20	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Claris Lifesciences, Inc.	2013-07-01	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	West Ward Pharmaceutical	2011-06-21	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Aurobindo Pharma	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-11-15	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	Cipla Limited	2012-03-30	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-11-08	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-03-27	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Rebel Distributors	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Unit Dose Services	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-06-20	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	A S Medication Solutions	2012-03-30	2017-06-20	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Proficient Rx LP	2015-01-09	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Physicians Total Care, Inc.	2011-06-22	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	Hikma Pharmaceutical	2011-06-21	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Lucid Pharma Llc	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-01-14	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Sagent Pharmaceuticals	2011-12-05	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2017-01-23	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	Aidarex Pharmaceuticals LLC	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-01-09	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Red Pharm Drug, Inc.	2011-06-20	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	A S Medication Solutions	2012-03-30	2017-06-20	US
Levofloxacin	Tablet	500 mg/1	Oral	Cardinal Health	2011-06-23	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2012-12-02	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	bryant ranch prepack	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Amerincan Health Packaging	2011-07-01	Not applicable	US
Levofloxacin	Solution	25 mg/mL	Oral	Department Of State Health Services, Pharmacy Branch	2011-06-21	Not applicable	US
Levofloxacin	Solution	5 mg/mL	Ophthalmic	Akorn	2011-03-01	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Remedy Repack	2013-09-19	2017-03-01	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Sandoz	2011-07-07	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Lupin Pharmaceuticals	2011-06-20	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Directrx	2015-01-01	Not applicable	US
Levofloxacin	Injection, solution	500 mg/100mL	Intravenous	West Ward Pharmaceutical	2011-09-16	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Ready Meds	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Macleods Pharmaceuticals Limited	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Teva	2011-06-20	2016-06-30	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2011-06-20	2017-01-14	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Clinical Solutions Wholsesale	2011-06-20	2017-06-24	US
Levofloxacin	Injection, solution	500 mg/100mL	Intravenous	Auro Medics Pharma Llc	2016-02-10	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Major	2013-12-01	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	WG Critical Care, LLC	2016-04-14	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	2016-10-26	2017-04-26	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Camber Pharmaceuticals	2015-01-09	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2015-01-08	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Rebel Distributors	2011-06-20	Not applicable	US
Levofloxacin	Injection, solution, concentrate	750 mg/30mL	Intravenous	Auro Medics Pharma Llc	2013-01-24	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	Major	2011-06-23	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	A S Medication Solutions	2012-11-10	2017-06-20	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-06-20	2016-12-21	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Remedy Repack	2017-04-04	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Tablet	250 mg/1	Oral	Torrent Pharmaceuticals Limited	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Directrx	2017-05-11	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Remedy Repack	2013-03-08	2016-12-21	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Dr Reddy's Laboratories	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Citron Pharma LLC	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Proficient Rx	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Av Kare, Inc.	2013-07-12	2016-10-13	US
Levofloxacin	Tablet	500 mg/1	Oral	Wockhardt	2011-06-20	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2012-03-30	Not applicable	US
Levofloxacin	Solution	25 mg/mL	Oral	Hi Tech Pharmacal Co., Inc.	2011-06-21	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Remedy Repack	2017-04-21	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Red Pharm Drug, Inc.	2015-01-09	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	Wockhardt	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Remedy Repack	2017-04-21	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	bryant ranch prepack	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Physicians Total Care, Inc.	2011-06-22	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	Hikma Pharmaceutical	2011-06-21	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Proficient Rx LP	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Cadila Pharnmaceuticals	2012-11-10	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Central Texas Community Health Centers	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Sandoz	2011-06-20	Not applicable	US
Levofloxacin	Injection, solution	5 mg/mL	Intravenous	Claris Lifesciences, Inc.	2013-07-01	Not applicable	US
Levofloxacin	Tablet	250 mg/1	Oral	West Ward Pharmaceutical	2011-06-21	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Aurobindo Pharma	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	A S Medication Solutions	2011-06-20	2017-06-20	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Blenheim Pharmacal, Inc.	2015-07-15	Not applicable	US
Levofloxacin	Tablet	750 mg/1	Oral	Cipla Limited	2012-03-30	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	250 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-06-20	Not applicable	US
Levofloxacin	Tablet	500 mg/1	Oral	Aidarex Pharmaceuticals LLC	2011-06-20	Not applicable	US
Levofloxacin	Tablet, film coated	500 mg/1	Oral	Unit Dose Services	2012-03-22	Not applicable	US
Levofloxacin	Tablet, film coated	750 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-06-20	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Cravit	Not Available
Elequine	Not Available
Floxel	Not Available
Leroxacin	Not Available
Levokacin	Not Available
Levox	Not Available
Levoxacin	Not Available
Mosardal	Not Available
Nofaxin	Not Available
Reskuin	Not Available
Tavanic	Not Available

Brand mixtures

Not Available

Categories

UNII

RIX4E89Y14

CAS number

100986-85-4

Weight

Average: 361.3675
Monoisotopic: 361.143784348

Chemical Formula

C₁₈H₂₀FN₃O₄

InChI Key

GSDSWSVVBLHKDQ-JTQLQIEISA-N

InChI

InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

IUPAC Name

(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid

SMILES

C[[email protected]]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1

Pharmacology

Indication

For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

Structured Indications

Pharmacodynamics

Levofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.

Mechanism of action

Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
DNA gyrase subunit A	Protein	yes	inhibitor	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	P43700	details
DNA topoisomerase 4 subunit A	Protein	yes	inhibitor	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	P43702	details
DNA topoisomerase 2-alpha	Protein	yes	inhibitor	Human	P11388	details

Absorption

Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.

Volume of distribution

Not Available

Protein binding

24-38% (to plasma proteins)

Metabolism

Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans.

Route of elimination

Mainly excreted as unchanged drug in the urine.

Half life

6-8 hours

Clearance

Not Available

Toxicity

Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face

Affected organisms

Enteric bacteria and other eubacteria

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Levofloxacin.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Levofloxacin.	Experimental, Illicit
Acarbose	Levofloxacin may increase the hypoglycemic activities of Acarbose.	Approved, Investigational
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Levofloxacin.	Approved
Aceclofenac	Aceclofenac may increase the neuroexcitatory activities of Levofloxacin.	Approved
Acenocoumarol	Levofloxacin may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetaminophen	The serum concentration of Levofloxacin can be increased when it is combined with Acetaminophen.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Levofloxacin.	Approved
Acetylsalicylic acid	Acetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Adapalene	Adapalene may increase the neuroexcitatory activities of Levofloxacin.	Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Levofloxacin.	Approved
Albendazole	The serum concentration of Levofloxacin can be increased when it is combined with Albendazole.	Approved, Vet Approved
Albiglutide	Levofloxacin may increase the hypoglycemic activities of Albiglutide.	Approved
Alclometasone	The risk or severity of adverse effects can be increased when Alclometasone is combined with Levofloxacin.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Aldosterone is combined with Levofloxacin.	Experimental
Alectinib	The serum concentration of Levofloxacin can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Levofloxacin can be increased when it is combined with Alfentanil.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Alogliptin	Levofloxacin may increase the hypoglycemic activities of Alogliptin.	Approved
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Amantadine	Amantadine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Levofloxacin.	Approved, Investigational
Ambroxol acefyllinate	The metabolism of Ambroxol acefyllinate can be decreased when combined with Levofloxacin.	Experimental
Amcinonide	The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin.	Approved
Aminohippuric acid	The serum concentration of Levofloxacin can be increased when it is combined with Aminohippuric acid.	Approved
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Levofloxacin.	Approved
Amiodarone	Levofloxacin may increase the QTc-prolonging activities of Amiodarone.	Approved, Investigational
Amitriptyline	Amitriptyline may increase the QTc-prolonging activities of Levofloxacin.	Approved
Amlodipine	The serum concentration of Levofloxacin can be increased when it is combined with Amlodipine.	Approved
Amoxapine	Amoxapine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Amprenavir	The serum concentration of Levofloxacin can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Levofloxacin can be increased when it is combined with Amsacrine.	Approved
Anagrelide	Levofloxacin may increase the QTc-prolonging activities of Anagrelide.	Approved
Andrographolide	HMPL-004 may increase the neuroexcitatory activities of Levofloxacin.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Levofloxacin.	Experimental, Illicit
Antipyrine	Antipyrine may increase the neuroexcitatory activities of Levofloxacin.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Levofloxacin.	Approved
Apomorphine	Apomorphine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Apremilast	Apremilast may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Arformoterol	Arformoterol may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Arsenic trioxide	Levofloxacin may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Levofloxacin may increase the QTc-prolonging activities of Artemether.	Approved
Asenapine	Levofloxacin may increase the QTc-prolonging activities of Asenapine.	Approved
Astemizole	The serum concentration of Levofloxacin can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	Atazanavir may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Atenolol	The serum concentration of Levofloxacin can be increased when it is combined with Atenolol.	Approved
Atomoxetine	Atomoxetine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Atorvastatin	The serum concentration of Levofloxacin can be increased when it is combined with Atorvastatin.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Levofloxacin.	Approved, Investigational
Azapropazone	Azapropazone may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Azelastine	Azelastine may increase the neuroexcitatory activities of Levofloxacin.	Approved
Azithromycin	Azithromycin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Balsalazide	Balsalazide may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin.	Approved, Investigational
Bedaquiline	Levofloxacin may increase the QTc-prolonging activities of Bedaquiline.	Approved
Benoxaprofen	Benoxaprofen may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Benzocaine	The serum concentration of Levofloxacin can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Levofloxacin can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin.	Approved, Vet Approved
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Levofloxacin.	Approved, Vet Approved
Betulinic Acid	Betulinic Acid may increase the neuroexcitatory activities of Levofloxacin.	Investigational
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Levofloxacin.	Approved, Investigational
Biperiden	The serum concentration of Levofloxacin can be increased when it is combined with Biperiden.	Approved
Bismuth Subcitrate	Bismuth Subcitrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Boceprevir	The serum concentration of Boceprevir can be increased when it is combined with Levofloxacin.	Approved, Investigational
Bortezomib	Bortezomib may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Levofloxacin.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Levofloxacin.	Approved
Bromfenac	Bromfenac may increase the neuroexcitatory activities of Levofloxacin.	Approved
Bromocriptine	The serum concentration of Levofloxacin can be increased when it is combined with Bromocriptine.	Approved, Investigational
Budesonide	The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin.	Approved
Buprenorphine	The serum concentration of Levofloxacin can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buserelin	Buserelin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Buspirone	The serum concentration of Levofloxacin can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Levofloxacin.	Approved
Caffeine	The serum concentration of Caffeine can be increased when it is combined with Levofloxacin.	Approved
Calcium	Calcium can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Nutraceutical
Calcium Acetate	Calcium Acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Calcium carbonate	Calcium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Calcium Chloride	Calcium Chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Calcium citrate	Calcium citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Calcium glubionate	Calcium glubionate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Calcium Gluceptate	Calcium Gluceptate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Calcium gluconate	Calcium gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Vet Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Levofloxacin.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be increased when it is combined with Levofloxacin.	Approved
Candesartan	The serum concentration of Levofloxacin can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Levofloxacin can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Levofloxacin can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Levofloxacin.	Approved
Carprofen	Carprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved, Withdrawn
Carvedilol	The serum concentration of Levofloxacin can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Levofloxacin can be increased when it is combined with Caspofungin.	Approved
Castanospermine	Castanospermine may increase the neuroexcitatory activities of Levofloxacin.	Experimental
Celecoxib	Celecoxib may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Ceritinib	Levofloxacin may increase the QTc-prolonging activities of Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Levofloxacin.	Withdrawn
Chloroquine	Chloroquine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Chlorpromazine	Chlorpromazine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Levofloxacin can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Levofloxacin can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The serum concentration of Levofloxacin can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Levofloxacin can be decreased when it is combined with Cholic Acid.	Approved
Choline magnesium trisalicylate	Trisalicylate-choline may increase the neuroexcitatory activities of Levofloxacin.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Ciclesonide is combined with Levofloxacin.	Approved, Investigational
Cilazapril	The serum concentration of Levofloxacin can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Levofloxacin can be decreased when it is combined with Cimetidine.	Approved
Ciprofloxacin	Ciprofloxacin may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Cisapride	Levofloxacin may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Levofloxacin.	Approved
Citalopram	Levofloxacin may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	Levofloxacin may increase the QTc-prolonging activities of Clarithromycin.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Levofloxacin.	Approved, Illicit
Clobetasol propionate	The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Clocortolone is combined with Levofloxacin.	Approved
Clofazimine	The serum concentration of Levofloxacin can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Levofloxacin.	Approved, Investigational
Clomipramine	Clomipramine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Clonidine	The serum concentration of Clonidine can be increased when it is combined with Levofloxacin.	Approved
Clonixin	Clonixin may increase the neuroexcitatory activities of Levofloxacin.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be increased when it is combined with Levofloxacin.	Approved, Nutraceutical
Clotrimazole	The serum concentration of Levofloxacin can be decreased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	Clozapine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Cobicistat	The serum concentration of Levofloxacin can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Levofloxacin.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Levofloxacin.	Approved
Colforsin	The serum concentration of Levofloxacin can be increased when it is combined with Colforsin.	Experimental
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Levofloxacin.	Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin.	Approved
Crizotinib	Levofloxacin may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Levofloxacin.	Approved, Investigational
Cyclosporine	The serum concentration of Levofloxacin can be decreased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin.	Approved
Dabrafenib	Dabrafenib may increase the QTc-prolonging activities of Levofloxacin.	Approved
Daclatasvir	The serum concentration of Levofloxacin can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Levofloxacin can be increased when it is combined with Dactinomycin.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be increased when it is combined with Levofloxacin.	Approved
Dasatinib	Dasatinib may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Daunorubicin	The serum concentration of Levofloxacin can be decreased when it is combined with Daunorubicin.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Levofloxacin.	Approved
Degarelix	Degarelix may increase the QTc-prolonging activities of Levofloxacin.	Approved
Desflurane	Desflurane may increase the QTc-prolonging activities of Levofloxacin.	Approved
Desipramine	Desipramine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Levofloxacin.	Approved
Desloratadine	The serum concentration of Levofloxacin can be increased when it is combined with Desloratadine.	Approved, Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Levofloxacin.	Experimental, Vet Approved
Dexamethasone	The risk or severity of adverse effects can be increased when Dexamethasone is combined with Levofloxacin.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of Levofloxacin can be increased when it is combined with Dextromethorphan.	Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Levofloxacin.	Approved, Illicit, Vet Approved
Diclofenac	Diclofenac may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Dicoumarol	Levofloxacin may increase the anticoagulant activities of Dicoumarol.	Approved
Didanosine	The serum concentration of Didanosine can be decreased when it is combined with Levofloxacin.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Levofloxacin.	Approved
Diflorasone	The risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin.	Approved
Diflunisal	Diflunisal may increase the neuroexcitatory activities of Levofloxacin.	Approved
Difluocortolone	The risk or severity of adverse effects can be increased when Difluocortolone is combined with Levofloxacin.	Approved
Difluprednate	The risk or severity of adverse effects can be increased when Difluprednate is combined with Levofloxacin.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Levofloxacin.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Levofloxacin.	Approved
Dihydroergotamine	The serum concentration of Levofloxacin can be increased when it is combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Levofloxacin.	Illicit
Diltiazem	The serum concentration of Levofloxacin can be increased when it is combined with Diltiazem.	Approved
Diphenhydramine	Diphenhydramine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Dipyridamole	The serum concentration of Levofloxacin can be increased when it is combined with Dipyridamole.	Approved
Disopyramide	Levofloxacin may increase the QTc-prolonging activities of Disopyramide.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin.	Approved, Investigational
Dofetilide	Levofloxacin may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Dolasetron may increase the QTc-prolonging activities of Levofloxacin.	Approved
Domperidone	Levofloxacin may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Doxazosin	The serum concentration of Levofloxacin can be increased when it is combined with Doxazosin.	Approved
Doxepin	Doxepin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Doxorubicin	The serum concentration of Levofloxacin can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Dronabinol	The serum concentration of Levofloxacin can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	Levofloxacin may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Droperidol may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Droxicam	Droxicam may increase the neuroexcitatory activities of Levofloxacin.	Approved
Dulaglutide	Levofloxacin may increase the hypoglycemic activities of Dulaglutide.	Approved
Dyphylline	The metabolism of Dyphylline can be decreased when combined with Levofloxacin.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Levofloxacin.	Approved
Elbasvir	The serum concentration of Levofloxacin can be increased when it is combined with Elbasvir.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Levofloxacin.	Approved, Investigational
Eliglustat	Levofloxacin may increase the QTc-prolonging activities of Eliglustat.	Approved
Empagliflozin	Levofloxacin may increase the hypoglycemic activities of Empagliflozin.	Approved
Enalapril	The serum concentration of Levofloxacin can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Levofloxacin can be increased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Levofloxacin.	Approved, Investigational
Epirizole	Epirizole may increase the neuroexcitatory activities of Levofloxacin.	Approved
Equilenin	The risk or severity of adverse effects can be increased when Equilenin is combined with Levofloxacin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Equilin is combined with Levofloxacin.	Approved
Ergonovine	The serum concentration of Levofloxacin can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Levofloxacin can be increased when it is combined with Ergotamine.	Approved
Eribulin	Eribulin may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Levofloxacin.	Approved, Investigational
Erythromycin	Erythromycin may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Escitalopram	Levofloxacin may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Levofloxacin.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Levofloxacin can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Levofloxacin can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The risk or severity of adverse effects can be increased when Estrone is combined with Levofloxacin.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Levofloxacin.	Approved
Etanercept	Etanercept may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Levofloxacin.	Approved
Ethyl biscoumacetate	Levofloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etodolac	Etodolac may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may increase the neuroexcitatory activities of Levofloxacin.	Approved
Etoposide	The serum concentration of Levofloxacin can be increased when it is combined with Etoposide.	Approved
Etoricoxib	Etoricoxib may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Etravirine	The serum concentration of Levofloxacin can be increased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Levofloxacin.	Approved
Exenatide	Levofloxacin may increase the hypoglycemic activities of Exenatide.	Approved, Investigational
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Levofloxacin.	Approved
Ezogabine	Ezogabine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Famotidine	Famotidine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Felbamate	Felbamate may increase the QTc-prolonging activities of Levofloxacin.	Approved
Felodipine	The serum concentration of Levofloxacin can be increased when it is combined with Felodipine.	Approved, Investigational
Fenbufen	Fenbufen may increase the neuroexcitatory activities of Levofloxacin.	Approved
Fenoprofen	Fenoprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved
Fentanyl	The serum concentration of Levofloxacin can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Ferric Carboxymaltose	The serum concentration of Levofloxacin can be decreased when it is combined with Ferric Carboxymaltose.	Approved
Ferric Citrate	The serum concentration of Levofloxacin can be decreased when it is combined with Ferric Citrate.	Approved
Ferric pyrophosphate	The serum concentration of Levofloxacin can be decreased when it is combined with Ferric pyrophosphate.	Approved
Fesoterodine	The serum concentration of Fesoterodine can be increased when it is combined with Levofloxacin.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Levofloxacin.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Levofloxacin.	Approved
Fingolimod	Fingolimod may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Flecainide	Levofloxacin may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Floctafenine	Floctafenine may increase the neuroexcitatory activities of Levofloxacin.	Approved, Withdrawn
Fluconazole	Fluconazole may increase the QTc-prolonging activities of Levofloxacin.	Approved
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Levofloxacin.	Approved
Flumethasone	The risk or severity of adverse effects can be increased when Flumethasone is combined with Levofloxacin.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin.	Approved, Investigational
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Levofloxacin.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Fluocortolone is combined with Levofloxacin.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin.	Approved
Fluoxetine	Levofloxacin may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	Levofloxacin may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Levofloxacin can be increased when it is combined with Fluphenazine.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Fluprednidene is combined with Levofloxacin.	Approved, Withdrawn
Flurandrenolide	The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin.	Approved
Flurazepam	The serum concentration of Levofloxacin can be increased when it is combined with Flurazepam.	Approved, Illicit
Flurbiprofen	Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Levofloxacin.	Approved
Fluticasone Propionate	The risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levofloxacin.	Approved
Fluvoxamine	The serum concentration of Levofloxacin can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Formestane	The risk or severity of adverse effects can be increased when Formestane is combined with Levofloxacin.	Approved, Investigational, Withdrawn
Formoterol	Formoterol may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Foscarnet	Foscarnet may increase the QTc-prolonging activities of Levofloxacin.	Approved
Gadobenic acid	Gadobenic acid may increase the QTc-prolonging activities of Levofloxacin.	Approved
Galantamine	Galantamine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Levofloxacin.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Levofloxacin.	Approved
Gemifloxacin	Levofloxacin may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Levofloxacin can be increased when it is combined with Genistein.	Investigational
Gliclazide	Levofloxacin may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Levofloxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	Levofloxacin may increase the hypoglycemic activities of Glipizide.	Approved
Glyburide	The serum concentration of Levofloxacin can be increased when it is combined with Glyburide.	Approved
Goserelin	Goserelin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Gramicidin D	The serum concentration of Levofloxacin can be increased when it is combined with Gramicidin D.	Approved
Granisetron	Granisetron may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Levofloxacin.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Levofloxacin.	Withdrawn
Haloperidol	Haloperidol may increase the QTc-prolonging activities of Levofloxacin.	Approved
HE3286	The risk or severity of adverse effects can be increased when HE3286 is combined with Levofloxacin.	Investigational
Histrelin	Histrelin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Hydrocortisone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin.	Approved, Vet Approved
Hydroxyzine	Hydroxyzine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Ibandronate	Ibandronate may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Ibuprofen	Ibuprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved
Ibuproxam	Ibuproxam may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Ibutilide	Levofloxacin may increase the QTc-prolonging activities of Ibutilide.	Approved
Icatibant	Icatibant may increase the neuroexcitatory activities of Levofloxacin.	Approved
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Levofloxacin.	Approved
Iloperidone	Levofloxacin may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Levofloxacin.	Approved
Imipramine	Imipramine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Indacaterol	Indacaterol may increase the QTc-prolonging activities of Levofloxacin.	Approved
Indapamide	Indapamide may increase the QTc-prolonging activities of Levofloxacin.	Approved
Indinavir	The serum concentration of Levofloxacin can be decreased when it is combined with Indinavir.	Approved
Indomethacin	Indomethacin may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Indoprofen	Indoprofen may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Insulin Aspart	Levofloxacin may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Levofloxacin may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Levofloxacin may increase the hypoglycemic activities of Insulin Glargine.	Approved
Insulin Glulisine	Levofloxacin may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Levofloxacin may increase the hypoglycemic activities of Insulin Human.	Approved, Investigational
Insulin Lispro	Levofloxacin may increase the hypoglycemic activities of Insulin Lispro.	Approved
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Levofloxacin.	Approved, Investigational
Iron	The serum concentration of Levofloxacin can be decreased when it is combined with Iron.	Approved
Iron Dextran	The serum concentration of Levofloxacin can be decreased when it is combined with Iron Dextran.	Approved, Vet Approved
Iron saccharate	The serum concentration of Levofloxacin can be decreased when it is combined with Iron saccharate.	Approved
Isavuconazonium	The serum concentration of Levofloxacin can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Isoflurane	Isoflurane may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Isoxicam	Isoxicam may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Isradipine	Isradipine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Itraconazole	Itraconazole may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Ivabradine	Ivabradine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Ivacaftor	The serum concentration of Levofloxacin can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Levofloxacin can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Kebuzone	Kebuzone may increase the neuroexcitatory activities of Levofloxacin.	Experimental
Ketamine	The serum concentration of Levofloxacin can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Levofloxacin.	Approved
Ketoconazole	Ketoconazole may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Ketoprofen	Ketoprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Ketorolac	Ketorolac may increase the neuroexcitatory activities of Levofloxacin.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Levofloxacin.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Levofloxacin.	Approved, Investigational
Lanreotide	Levofloxacin may increase the hypoglycemic activities of Lanreotide.	Approved
Lansoprazole	The serum concentration of Levofloxacin can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lanthanum carbonate	The serum concentration of Levofloxacin can be decreased when it is combined with Lanthanum carbonate.	Approved
Lapatinib	Lapatinib may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Levofloxacin.	Approved
Leflunomide	Leflunomide may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Levofloxacin.	Approved
Lenvatinib	Levofloxacin may increase the QTc-prolonging activities of Lenvatinib.	Approved
Leuprolide	Leuprolide may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Levofloxacin.	Approved
Levothyroxine	The serum concentration of Levofloxacin can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Levofloxacin can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Levofloxacin.	Approved
Liothyronine	The serum concentration of Levofloxacin can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Levofloxacin can be decreased when it is combined with Liotrix.	Approved
Liraglutide	Levofloxacin may increase the hypoglycemic activities of Liraglutide.	Approved
Lisinopril	The serum concentration of Levofloxacin can be increased when it is combined with Lisinopril.	Approved, Investigational
Lithium	Lithium may increase the QTc-prolonging activities of Levofloxacin.	Approved
Lomitapide	The serum concentration of Levofloxacin can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Levofloxacin can be increased when it is combined with Loperamide.	Approved
Lopinavir	Levofloxacin may increase the QTc-prolonging activities of Lopinavir.	Approved
Loratadine	The serum concentration of Levofloxacin can be increased when it is combined with Loratadine.	Approved
Lornoxicam	Lornoxicam may increase the neuroexcitatory activities of Levofloxacin.	Approved
Losartan	The serum concentration of Levofloxacin can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of Levofloxacin can be increased when it is combined with Lovastatin.	Approved, Investigational
Loxoprofen	Loxoprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved
Lumacaftor	The serum concentration of Levofloxacin can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	Levofloxacin may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lumiracoxib	Lumiracoxib may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Magaldrate	Magaldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Withdrawn
Magnesium carbonate	Magnesium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium Hydroxide	Magnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium oxide	Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Magnesium salicylate	The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium salicylate.	Approved
Magnesium Sulfate	The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium Sulfate.	Approved, Vet Approved
Magnesium Trisilicate	Magnesium Trisilicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Levofloxacin.	Approved, Investigational
Maprotiline	Maprotiline may increase the QTc-prolonging activities of Levofloxacin.	Approved
Masoprocol	Masoprocol may increase the neuroexcitatory activities of Levofloxacin.	Approved
ME-609	The risk or severity of adverse effects can be increased when ME-609 is combined with Levofloxacin.	Investigational
Mebendazole	The serum concentration of Levofloxacin can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mecasermin	Levofloxacin may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Meclofenamic acid	Meclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Medrysone	The risk or severity of adverse effects can be increased when Medrysone is combined with Levofloxacin.	Approved
Mefenamic acid	Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin.	Approved
Mefloquine	Mefloquine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Megestrol acetate	The serum concentration of Levofloxacin can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meloxicam	Meloxicam may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Meprobamate	The serum concentration of Levofloxacin can be increased when it is combined with Meprobamate.	Approved, Illicit
Mesalazine	Mesalazine may increase the neuroexcitatory activities of Levofloxacin.	Approved
Metamizole	Metamizole may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Metformin	Levofloxacin may increase the hypoglycemic activities of Metformin.	Approved
Methadone	Methadone may increase the QTc-prolonging activities of Levofloxacin.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Levofloxacin.	Approved
Methotrimeprazine	Methotrimeprazine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Levofloxacin.	Approved, Vet Approved
Metoclopramide	Metoclopramide may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Metoprolol	The serum concentration of Levofloxacin can be increased when it is combined with Metoprolol.	Approved, Investigational
Metronidazole	Metronidazole may increase the QTc-prolonging activities of Levofloxacin.	Approved
Mibefradil	The serum concentration of Levofloxacin can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Levofloxacin can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Levofloxacin can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Miglitol	Levofloxacin may increase the hypoglycemic activities of Miglitol.	Approved
Mirabegron	Mirabegron may increase the QTc-prolonging activities of Levofloxacin.	Approved
Mirtazapine	Mirtazapine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Mitomycin	The serum concentration of Levofloxacin can be increased when it is combined with Mitomycin.	Approved
Mitoxantrone	The serum concentration of Levofloxacin can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Moexipril	Moexipril may increase the QTc-prolonging activities of Levofloxacin.	Approved
Mometasone	The risk or severity of adverse effects can be increased when Mometasone is combined with Levofloxacin.	Approved, Vet Approved
Morphine	The serum concentration of Levofloxacin can be increased when it is combined with Morphine.	Approved, Investigational
Moxifloxacin	Moxifloxacin may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Mycophenolate mofetil	Mycophenolate mofetil may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Mycophenolic acid	The serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.	Approved
Nabumetone	Nabumetone may increase the neuroexcitatory activities of Levofloxacin.	Approved
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Levofloxacin.	Approved
Nafamostat	Nafamostat may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Naftifine	Naftifine may increase the neuroexcitatory activities of Levofloxacin.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Levofloxacin.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Levofloxacin.	Approved, Vet Approved
Naltrexone	The serum concentration of Levofloxacin can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naproxen	Naproxen may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Naringenin	The serum concentration of Levofloxacin can be increased when it is combined with Naringenin.	Experimental
Nateglinide	Levofloxacin may increase the hypoglycemic activities of Nateglinide.	Approved, Investigational
NCX 1022	The risk or severity of adverse effects can be increased when NCX 1022 is combined with Levofloxacin.	Investigational
NCX 4016	NCX 4016 may increase the neuroexcitatory activities of Levofloxacin.	Investigational
Nefazodone	The serum concentration of Levofloxacin can be decreased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	Nelfinavir may increase the QTc-prolonging activities of Levofloxacin.	Approved
Neostigmine	The serum concentration of Levofloxacin can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	Nepafenac may increase the neuroexcitatory activities of Levofloxacin.	Approved
Nicardipine	Nicardipine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Nifedipine	The serum concentration of Levofloxacin can be decreased when it is combined with Nifedipine.	Approved
Niflumic Acid	Niflumic Acid may increase the neuroexcitatory activities of Levofloxacin.	Approved
Nilotinib	Levofloxacin may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nimesulide	Nimesulide may increase the neuroexcitatory activities of Levofloxacin.	Approved, Withdrawn
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Levofloxacin.	Approved
Nisoldipine	The serum concentration of Levofloxacin can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Levofloxacin can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Levofloxacin.	Approved
Norethisterone	The serum concentration of Levofloxacin can be decreased when it is combined with Norethisterone.	Approved
Norfloxacin	Norfloxacin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Nortriptyline	Nortriptyline may increase the QTc-prolonging activities of Levofloxacin.	Approved
Octreotide	Octreotide may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Ofloxacin	Levofloxacin may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	Olanzapine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Levofloxacin.	Experimental
Oleoyl estrone	The risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Levofloxacin.	Investigational
Olodaterol	Olodaterol may increase the QTc-prolonging activities of Levofloxacin.	Approved
Olopatadine	Olopatadine may increase the neuroexcitatory activities of Levofloxacin.	Approved
Olsalazine	Olsalazine may increase the neuroexcitatory activities of Levofloxacin.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Levofloxacin.	Approved
Omeprazole	The serum concentration of Levofloxacin can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	Ondansetron may increase the QTc-prolonging activities of Levofloxacin.	Approved
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Levofloxacin.	Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Levofloxacin.	Approved
Oxaprozin	Oxaprozin may increase the neuroexcitatory activities of Levofloxacin.	Approved
Oxyphenbutazone	Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Oxytocin	Oxytocin may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
P-Nitrophenol	The serum concentration of Levofloxacin can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Levofloxacin.	Approved, Vet Approved
Paliperidone	Levofloxacin may increase the QTc-prolonging activities of Paliperidone.	Approved
Palmitic Acid	The serum concentration of Levofloxacin can be increased when it is combined with Palmitic Acid.	Experimental
Panobinostat	Levofloxacin may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Pantoprazole	The serum concentration of Levofloxacin can be increased when it is combined with Pantoprazole.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Paramethasone is combined with Levofloxacin.	Approved
Parecoxib	Parecoxib may increase the neuroexcitatory activities of Levofloxacin.	Approved
Paroxetine	Paroxetine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Pasireotide	Pasireotide may increase the QTc-prolonging activities of Levofloxacin.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.	Approved
Pentamidine	Pentamidine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Perflutren	Perflutren may increase the QTc-prolonging activities of Levofloxacin.	Approved
Perindopril	The serum concentration of Levofloxacin can be increased when it is combined with Perindopril.	Approved
Phenindione	Levofloxacin may increase the anticoagulant activities of Phenindione.	Approved
Phenobarbital	The serum concentration of Levofloxacin can be decreased when it is combined with Phenobarbital.	Approved
Phenprocoumon	Levofloxacin may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenylbutazone	Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Levofloxacin.	Approved, Vet Approved
Picosulfuric acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Levofloxacin.	Approved
Pimecrolimus	Pimecrolimus may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Pimozide	Levofloxacin may increase the QTc-prolonging activities of Pimozide.	Approved
Pioglitazone	Levofloxacin may increase the hypoglycemic activities of Pioglitazone.	Approved, Investigational
Pirfenidone	Pirfenidone may increase the neuroexcitatory activities of Levofloxacin.	Investigational
Piroxicam	Piroxicam may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Levofloxacin.	Approved
Platelet Activating Factor	The serum concentration of Levofloxacin can be decreased when it is combined with Platelet Activating Factor.	Experimental
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Levofloxacin.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Levofloxacin.	Approved
Posaconazole	Posaconazole may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational, Vet Approved
Pramlintide	Levofloxacin may increase the hypoglycemic activities of Pramlintide.	Approved, Investigational
Prasterone	The risk or severity of adverse effects can be increased when Prasterone is combined with Levofloxacin.	Approved, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Levofloxacin.	Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Levofloxacin.	Approved
Prazosin	The serum concentration of Levofloxacin can be increased when it is combined with Prazosin.	Approved
Prednicarbate	The risk or severity of adverse effects can be increased when Prednicarbate is combined with Levofloxacin.	Approved
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Levofloxacin.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Levofloxacin.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Pregnenolone is combined with Levofloxacin.	Experimental
Primaquine	Primaquine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Probenecid	The serum concentration of Levofloxacin can be increased when it is combined with Probenecid.	Approved
Procainamide	Levofloxacin may increase the QTc-prolonging activities of Procainamide.	Approved
Progesterone	The serum concentration of Levofloxacin can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promazine	Promazine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Promethazine	Promethazine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Propacetamol	Propacetamol may increase the neuroexcitatory activities of Levofloxacin.	Approved
Propafenone	Levofloxacin may increase the QTc-prolonging activities of Propafenone.	Approved
Propofol	Propofol may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational, Vet Approved
Propranolol	The serum concentration of Propranolol can be increased when it is combined with Levofloxacin.	Approved, Investigational
Protriptyline	Protriptyline may increase the QTc-prolonging activities of Levofloxacin.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Levofloxacin.	Approved
PTC299	PTC299 may increase the neuroexcitatory activities of Levofloxacin.	Investigational
Quercetin	The serum concentration of Levofloxacin can be increased when it is combined with Quercetin.	Experimental
Quetiapine	Levofloxacin may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinacrine	The serum concentration of Levofloxacin can be increased when it is combined with Quinacrine.	Approved
Quinapril	The serum concentration of Levofloxacin can be decreased when it is combined with Quinapril.	Approved, Investigational
Quinidine	Levofloxacin may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Levofloxacin may increase the QTc-prolonging activities of Quinine.	Approved
Ranitidine	The serum concentration of Levofloxacin can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Levofloxacin.	Approved, Investigational
Reboxetine	The serum concentration of Levofloxacin can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Levofloxacin can be increased when it is combined with Regorafenib.	Approved
Repaglinide	Levofloxacin may increase the hypoglycemic activities of Repaglinide.	Approved, Investigational
Reserpine	The serum concentration of Levofloxacin can be decreased when it is combined with Reserpine.	Approved
Resveratrol	Resveratrol may increase the neuroexcitatory activities of Levofloxacin.	Experimental, Investigational
Rifampicin	The serum concentration of Levofloxacin can be decreased when it is combined with Rifampicin.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Rilpivirine	Rilpivirine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Rimexolone	The risk or severity of adverse effects can be increased when Rimexolone is combined with Levofloxacin.	Approved
Risperidone	Risperidone may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Ritonavir	Ritonavir may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Levofloxacin.	Approved
Rofecoxib	Rofecoxib may increase the neuroexcitatory activities of Levofloxacin.	Investigational, Withdrawn
Rolapitant	The serum concentration of Levofloxacin can be increased when it is combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Rosiglitazone	Levofloxacin may increase the hypoglycemic activities of Rosiglitazone.	Approved, Investigational
Salbutamol	Salbutamol may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Salicylamide	Salicylamide may increase the neuroexcitatory activities of Levofloxacin.	Approved
Salicylic acid	Salicylic acid may increase the neuroexcitatory activities of Levofloxacin.	Approved, Vet Approved
Salmeterol	Salmeterol may increase the QTc-prolonging activities of Levofloxacin.	Approved
Salsalate	Salsalate may increase the neuroexcitatory activities of Levofloxacin.	Approved
Saquinavir	Levofloxacin may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Saxagliptin	Levofloxacin may increase the hypoglycemic activities of Saxagliptin.	Approved
Scopolamine	The serum concentration of Levofloxacin can be increased when it is combined with Scopolamine.	Approved
Selegiline	The serum concentration of Levofloxacin can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Levofloxacin.	Approved
Sertraline	Sertraline may increase the QTc-prolonging activities of Levofloxacin.	Approved
Sevelamer	Sevelamer can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Sevoflurane	Sevoflurane may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Levofloxacin.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Levofloxacin.	Approved
Simvastatin	The serum concentration of Levofloxacin can be increased when it is combined with Simvastatin.	Approved
Sirolimus	The serum concentration of Levofloxacin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Levofloxacin.	Approved
Solifenacin	Solifenacin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Sorafenib	Sorafenib may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Sotalol	Levofloxacin may increase the QTc-prolonging activities of Sotalol.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Levofloxacin.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Levofloxacin.	Experimental
Spironolactone	The serum concentration of Levofloxacin can be increased when it is combined with Spironolactone.	Approved
SRT501	SRT501 may increase the neuroexcitatory activities of Levofloxacin.	Investigational
St. John's Wort	The serum concentration of Levofloxacin can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Levofloxacin can be increased when it is combined with Staurosporine.	Experimental
Streptozocin	The serum concentration of Levofloxacin can be decreased when it is combined with Streptozocin.	Approved
Strontium ranelate	The serum concentration of Levofloxacin can be decreased when it is combined with Strontium ranelate.	Approved
Sucralfate	The serum concentration of Levofloxacin can be decreased when it is combined with Sucralfate.	Approved
Sulfadiazine	Levofloxacin may increase the hypoglycemic activities of Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	Sulfamethoxazole may increase the QTc-prolonging activities of Levofloxacin.	Approved
Sulfasalazine	Sulfasalazine may increase the neuroexcitatory activities of Levofloxacin.	Approved
Sulfinpyrazone	The serum concentration of Levofloxacin can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	Sulfisoxazole may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Sulindac	Sulindac may increase the neuroexcitatory activities of Levofloxacin.	Approved
Sumatriptan	The serum concentration of Levofloxacin can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	Sunitinib may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Suprofen	Suprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved, Withdrawn
Tacrine	The serum concentration of Levofloxacin can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The serum concentration of Levofloxacin can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tacrolimus	Levofloxacin may increase the QTc-prolonging activities of Tacrolimus.	Approved, Investigational
Tamoxifen	Tamoxifen may increase the QTc-prolonging activities of Levofloxacin.	Approved
Taurocholic Acid	The serum concentration of Levofloxacin can be increased when it is combined with Taurocholic Acid.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Levofloxacin.	Approved
Telaprevir	The serum concentration of Telaprevir can be increased when it is combined with Levofloxacin.	Withdrawn
Telavancin	Levofloxacin may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	Telithromycin may increase the QTc-prolonging activities of Levofloxacin.	Approved
Telmisartan	The serum concentration of Levofloxacin can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Levofloxacin.	Approved
Tenoxicam	Tenoxicam may increase the neuroexcitatory activities of Levofloxacin.	Approved
Terazosin	The serum concentration of Levofloxacin can be increased when it is combined with Terazosin.	Approved
Terbutaline	Terbutaline may increase the QTc-prolonging activities of Levofloxacin.	Approved
Terfenadine	The serum concentration of Levofloxacin can be increased when it is combined with Terfenadine.	Withdrawn
Teriflunomide	The serum concentration of Levofloxacin can be increased when it is combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Levofloxacin can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Levofloxacin can be increased when it is combined with Testosterone.	Approved, Investigational
Tetrabenazine	Levofloxacin may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Theophylline	The metabolism of Theophylline can be decreased when combined with Levofloxacin.	Approved
Thioridazine	Levofloxacin may increase the QTc-prolonging activities of Thioridazine.	Withdrawn
Thiothixene	Thiothixene may increase the QTc-prolonging activities of Levofloxacin.	Approved
Tiaprofenic acid	Tiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Levofloxacin.	Approved
Timolol	The serum concentration of Timolol can be increased when it is combined with Levofloxacin.	Approved
Tixocortol	The risk or severity of adverse effects can be increased when Tixocortol is combined with Levofloxacin.	Approved
Tizanidine	Tizanidine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Tolazamide	Levofloxacin may increase the hypoglycemic activities of Tolazamide.	Approved
Tolbutamide	Levofloxacin may increase the hypoglycemic activities of Tolbutamide.	Approved
Tolfenamic Acid	Tolfenamic Acid may increase the neuroexcitatory activities of Levofloxacin.	Approved
Tolmetin	Tolmetin may increase the neuroexcitatory activities of Levofloxacin.	Approved
Tolterodine	Tolterodine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Levofloxacin.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Levofloxacin.	Approved, Investigational
Toremifene	Levofloxacin may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Tranilast	Tranilast may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Levofloxacin.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Levofloxacin.	Approved
Trazodone	Trazodone may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Treprostinil	Treprostinil may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Levofloxacin.	Approved, Vet Approved
Trifluoperazine	The serum concentration of Levofloxacin can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Levofloxacin can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	Trimethoprim may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Trimipramine	Trimipramine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Triptorelin	Triptorelin may increase the QTc-prolonging activities of Levofloxacin.	Approved, Vet Approved
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Levofloxacin.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Levofloxacin.	Approved
Valdecoxib	Valdecoxib may increase the neuroexcitatory activities of Levofloxacin.	Investigational, Withdrawn
Vandetanib	Levofloxacin may increase the QTc-prolonging activities of Vandetanib.	Approved
Vardenafil	Vardenafil may increase the QTc-prolonging activities of Levofloxacin.	Approved
Varenicline	The serum concentration of Varenicline can be increased when it is combined with Levofloxacin.	Approved, Investigational
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Levofloxacin.	Approved
Vemurafenib	Levofloxacin may increase the QTc-prolonging activities of Vemurafenib.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Levofloxacin.	Approved
Venlafaxine	Venlafaxine may increase the QTc-prolonging activities of Levofloxacin.	Approved
Verapamil	The serum concentration of Levofloxacin can be decreased when it is combined with Verapamil.	Approved
Vilanterol	Vilanterol may increase the QTc-prolonging activities of Levofloxacin.	Approved
Vinblastine	The serum concentration of Levofloxacin can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Levofloxacin.	Approved, Investigational
Vincristine	The serum concentration of Levofloxacin can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Levofloxacin can be increased when it is combined with Vinorelbine.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Levofloxacin.	Approved
Voriconazole	Voriconazole may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Vorinostat	Vorinostat may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Warfarin	Levofloxacin may increase the anticoagulant activities of Warfarin.	Approved
Zaltoprofen	Zaltoprofen may increase the neuroexcitatory activities of Levofloxacin.	Approved
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Levofloxacin.	Approved
Zileuton	Zileuton may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Levofloxacin can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	Levofloxacin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zomepirac	Zomepirac may increase the neuroexcitatory activities of Levofloxacin.	Withdrawn
Zuclopenthixol	Levofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels.

References

Synthesis Reference

Valerie Niddam-Hildesheim, "Preparation of levofloxacin and forms thereof." U.S. Patent US20030130507, issued July 10, 2003.

US20030130507

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB01929
KEGG Compound	C07660
PubChem Compound	149096
PubChem Substance	46505134
ChemSpider	131410
BindingDB	50366826
ChEBI	63598
ChEMBL	CHEMBL33
Therapeutic Targets Database	DAP000160
PharmGKB	PA450214
HET	LFX
Drug Product Database	11705
RxList	http://www.rxlist.com/cgi/generic2/quixin.htm
Drugs.com	http://www.drugs.com/cdi/levofloxacin-drops.html
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/flo1181.shtml
Wikipedia	Levofloxacin

ATC Codes

J01RA05

A02BD10

S01AE05

J01MA12

AHFS Codes

08:12.18

PDB Entries

Not Available

FDA label

Download (139 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Not Yet Recruiting	Prevention	Complications of Surgical Procedures	1
0	Recruiting	Treatment	Osteomyelitis	1
1	Completed	Not Available	Cystic Fibrosis (CF)	1
1	Completed	Diagnostic	Lung Function / Sarcoidosis, Pulmonary	1
1	Completed	Health Services Research	Healthy Volunteers	1
1	Completed	Prevention	Chronic Obstructive Pulmonary Disease (COPD)	1
1	Completed	Treatment	Cystic Fibrosis (CF)	1
1	Completed	Treatment	Healthy Volunteers	2
1	Completed	Treatment	Healthy Volunteers / The Focus of This Study Was to Assess the Effect of Food Following a Single Oral Dose of Levofloxacin Solution	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
1	Completed	Treatment	Renal Diseases	1
1	Terminated	Not Available	Escherichia Coli Infections	1
1	Terminated	Treatment	Over Active Bladder / Overactive Urinary Bladder	1
1, 2	Completed	Treatment	TB Multi-drug Resistant	1
1, 2	Recruiting	Treatment	Tuberculous Meningitis	1
1, 2	Unknown Status	Treatment	Corneal Diseases / Hypermetropia / Myopia / Pterygium	1
2	Active Not Recruiting	Treatment	Tuberculosis, Multidrug Resistant	1
2	Completed	Not Available	Healthy Volunteers	1
2	Completed	Treatment	Acute Pyelonephritis / Complicated Urinary Tract Infections	1
2	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
2	Completed	Treatment	Community Acquired Pneumonia (CAP)	1
2	Completed	Treatment	Community-Acquired Bacterial Pneumonia (CABP)	1
2	Completed	Treatment	Cystic Fibrosis (CF)	1
2	Completed	Treatment	Diabetic Foot Ulcers (DFU)	2
2	Completed	Treatment	Foot Ulcer, Diabetic	1
2	Not Yet Recruiting	Treatment	Acute Appendicitis	1
2	Recruiting	Supportive Care	Stem Cell Transplant Complications	1
2	Recruiting	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
2	Recruiting	Treatment	Sarcoidosis; Antimycobacterial Therapy	1
2	Recruiting	Treatment	Tuberculosis, Multidrug Resistant	1
2	Terminated	Treatment	Cancers / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Community Acquired Pneumonia (CAP)	1
2	Terminated	Treatment	Infected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee	1
2, 3	Completed	Treatment	Acute Exacerbation of Chronic Obstructive Pulmonary Disease	1
2, 3	Completed	Treatment	Bronchitis / Chronic Bronchitis	1
2, 3	Completed	Treatment	Cellulitis / Skin Diseases, Infectious	1
2, 3	Completed	Treatment	Pneumonia	1
2, 3	Recruiting	Treatment	Extensively-drug Resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant	1
2, 3	Unknown Status	Prevention	Allogeneic Stem Cell Transplantation / Malignancies	1
3	Active Not Recruiting	Supportive Care	Acute Leukemias of Ambiguous Lineage / Diarrhea / Infections, Bacterial / Infections, Fungal / Musculoskeletal Complications / Neutropenias / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
3	Active Not Recruiting	Treatment	Community Acquired Pneumonia (CAP)	1
3	Active Not Recruiting	Treatment	Complicated Urinary Tract Infections (cUTIs)	1
3	Completed	Not Available	Prostatic Hyperplasia / Prostatitis	1
3	Completed	Supportive Care	Brain and Central Nervous System Tumors / Cancer, Breast / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Infection NOS / Lung Cancers / Malignant Lymphomas / Small Intestine Cancer / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific	1
3	Completed	Treatment	Acute Lower Urinary Tract Infection	1
3	Completed	Treatment	Acute Pyelonephritis / Complicated Urinary Tract Infections	1
3	Completed	Treatment	Acute Pyelonephritis / Urinary Tract Infection Complicated	1
3	Completed	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	2
3	Completed	Treatment	Bacteriuria / Infections, Bacterial / Urinary Tract Infections (UTIs) / Urologic Diseases	1
3	Completed	Treatment	Bacteriuria / Neurogenic Bladder Dysfunction / Pyelonephritis / Urinary Tract Infections (UTIs) / Urologic Diseases	1
3	Completed	Treatment	Chronic Bronchitis	2
3	Completed	Treatment	Community-Acquired Infections / Cross Infection / Pneumonia, Bacterial	1
3	Completed	Treatment	Complicated Urinary Tract Infections / Pyelonephritis	1
3	Completed	Treatment	Cystic Fibrosis (CF)	2
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
3	Completed	Treatment	Maxillary Sinusitis	2
3	Completed	Treatment	Maxillary Sinusitis / Sinusitis	1
3	Completed	Treatment	Otitis Media (OM)	2
3	Completed	Treatment	Pelvic Inflammatory Disease (PID)	1
3	Completed	Treatment	Pneumonia	6
3	Completed	Treatment	Prostatitis	3
3	Completed	Treatment	Pyelonephritis / Urinary Tract Infections (UTIs)	1
3	Completed	Treatment	Sinusitis	1
3	Completed	Treatment	Skin Diseases, Bacterial	1
3	Completed	Treatment	Skin Diseases, Infectious	1
3	Completed	Treatment	Hospital-acquired bacterial pneumonia	1
3	Not Yet Recruiting	Prevention	Prevention	1
3	Not Yet Recruiting	Treatment	Tuberculosis Multi Drug Resistant Active	1
3	Recruiting	Prevention	Atrioventricular block complete / Chronic Systolic Heart Failure / Sick Sinus Syndrome / Syncope	1
3	Recruiting	Prevention	Cataract operation	1
3	Recruiting	Treatment	Chronic Rhinosinusitis	1
3	Recruiting	Treatment	Complicated Urinary Tract Infections	1
3	Recruiting	Treatment	Helicobacter-associated Gastritis	1
3	Recruiting	Treatment	Indigestion	1
3	Recruiting	Treatment	Infective Endocarditis	1
3	Recruiting	Treatment	Keratitis; Infectious Disease (Manifestation)	1
3	Recruiting	Treatment	MDR-TB	1
3	Recruiting	Treatment	Tuberculosis, Multidrug Resistant	1
3	Terminated	Treatment	Infection NOS	1
3	Terminated	Treatment	Infection in Solid Organ Transplant Recipients / Latent Tuberculosis Infection (LTI)	1
3	Terminated	Treatment	Staphylococcus	1
3	Terminated	Treatment	Tuberculous infections	1
3	Unknown Status	Supportive Care	Fever, Sweats, and Hot Flashes / Infection NOS / Leukemias / Malignant Lymphomas / Neutropenias / Unspecified Adult Solid Tumor, Protocol Specific	1
3	Unknown Status	Treatment	Acute Exacerbation of Chronic Bronchitis (AECB)	1
4	Active Not Recruiting	Treatment	Helicobacter Pylori Gastrointestinal Tract Infection	1
4	Completed	Not Available	Bacteremia / Endocarditis / Sepsis / Staphylococcus Aureus	1
4	Completed	Not Available	Helicobacter Infections	1
4	Completed	Basic Science	Cataracts	1
4	Completed	Basic Science	Healthy Volunteers	1
4	Completed	Prevention	Disease Due to BK Polyomavirus / Kidney Transplant Infection	1
4	Completed	Treatment	Acute Bacterial Sinusitis (ABS)	1
4	Completed	Treatment	Acute Exacerbation of Chronic Obstructive Pulmonary Disease	2
4	Completed	Treatment	BK Viremia	1
4	Completed	Treatment	BMI >30 kg/m2 / Critical Illness	1
4	Completed	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
4	Completed	Treatment	Cataract Extraction	1
4	Completed	Treatment	Cataracts	1
4	Completed	Treatment	Cataracts / Dry Eye Syndromes	1
4	Completed	Treatment	Community Acquired Pneumonia (CAP)	1
4	Completed	Treatment	Community Acquired Pneumonia (CAP) / Intensive Care Unit Syndrome	1
4	Completed	Treatment	Community-acquired / Pneumonia, Bacterial	1
4	Completed	Treatment	Cure Rate of Helicobacter Pylori Infection	1
4	Completed	Treatment	Fevers / Urinary Tract Infections (UTIs)	1
4	Completed	Treatment	Functional Dyspepsia / Peptic Ulcers	1
4	Completed	Treatment	Helicobacter Infections	1
4	Completed	Treatment	Pneumonia	1
4	Completed	Treatment	Tuberculosis, Pulmonary	1
4	Not Yet Recruiting	Treatment	Antimicrobial Susceptibility Testing / Triple Therapy	1
4	Not Yet Recruiting	Treatment	Helicobacter Pylori Gastrointestinal Tract Infection	1
4	Recruiting	Prevention	Malignant Neoplasm of Prostate	1
4	Recruiting	Treatment	Antimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
4	Recruiting	Treatment	Bacillus Calmette-Guerin (BCG) Cystitis / Intra-vesical Instillation / Non-Muscle-invasive Bladder Cancer (NMIBC)	1
4	Recruiting	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
4	Recruiting	Treatment	Cholangitis	1
4	Recruiting	Treatment	Community Acquired Pneumonia (CAP)	2
4	Recruiting	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
4	Recruiting	Treatment	Mycoplasma Pneumoniae Pneumonia	1
4	Recruiting	Treatment	Tuberculosis, Pulmonary	1
4	Recruiting	Treatment	Urinary Tract Infections (UTIs)	1
4	Terminated	Basic Science	Transplantation, Corneal	1
4	Terminated	Treatment	Acute Uncomplicated Pyelonephritis	1
4	Terminated	Treatment	Appendicitis	1
4	Terminated	Treatment	Complicated Urinary Infection	1
4	Terminated	Treatment	Pneumonia, Pneumococcal	1
4	Unknown Status	Treatment	Community Acquired Pneumonia (CAP)	1
4	Unknown Status	Treatment	Eradication Rate for Helicobacter	1
4	Unknown Status	Treatment	Urinary Tract Infections (UTIs)	1
Not Available	Active Not Recruiting	Other	Anti-Bacterial Agents / Microbiota	1
Not Available	Completed	Not Available	Acute maxillary sinusitis caused by M. catarrhalis	1
Not Available	Completed	Not Available	End Stage Renal Disease (ESRD) / Infection NOS	1
Not Available	Completed	Prevention	Endophthalmitis	1
Not Available	Completed	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	1
Not Available	Completed	Treatment	Gastritis	1
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
Not Available	Completed	Treatment	Osteoarticular Infections	1
Not Available	Not Yet Recruiting	Treatment	Antibiotics / Infection NOS / Percutaneous Nephrolithotomy / Sepsis	1
Not Available	Recruiting	Treatment	Bacterial Infection Due to Helicobacter Pylori (H. Pylori)	3
Not Available	Recruiting	Treatment	Bronchiectasis	1
Not Available	Terminated	Treatment	Acute Watery Diarrhea / Dysentery/Febrile Diarrhea	1
Not Available	Unknown Status	Not Available	Asymptomatic Infections / Bacteriuria / Transplantation Infection / Urinary Tract Infections (UTIs)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Advanced Pharmaceutical Services Inc.
Apotheca Inc.
A-S Medication Solutions LLC
Atlantic Biologicals Corporation
Cardinal Health
Comprehensive Consultant Services Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
H.J. Harkins Co. Inc.
Hospira Inc.
Innoviant Pharmacy Inc.
Janssen-Ortho Inc.
Lake Erie Medical and Surgical Supply
Letco Medical Inc.
Liberty Pharmaceuticals
McNeil Laboratories
Medisca Inc.
Murfreesboro Pharmaceutical Nursing Supply
Neuman Distributors Inc.
Nucare Pharmaceuticals Inc.
OMJ Pharmaceuticals
Ortho Mcneil Janssen Pharmaceutical Inc.
Ortho-McNeil-Janssen Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
Prepackage Specialists
Rebel Distributors Corp.
Redpharm Drug
Remedy Repack
Santen Inc.
Southwood Pharmaceuticals
Stat Rx Usa
Teva Pharmaceutical Industries Ltd.
Vistakon Pharmaceuticals LLC
Yuhan Chemical Industrial Co. Ltd.

Dosage forms

Form	Route	Strength
Solution	Ophthalmic	15 mg/mL
Solution	Intravenous	25 mg
Injection	Intravenous	25 mg/mL
Injection	Intravenous	5 mg/mL
Injection, solution	Intravenous	25 mg/mL
Injection, solution	Intravenous	250 mg/50mL
Injection, solution	Intravenous	5 mg/mL
Injection, solution	Intravenous	500 mg/100mL
Injection, solution	Intravenous	750 mg/150mL
Injection, solution, concentrate	Intravenous	25 mg/mL
Injection, solution, concentrate	Intravenous	500 mg/20mL
Injection, solution, concentrate	Intravenous	750 mg/30mL
Solution	Oral	25 mg/mL
Solution / drops	Ophthalmic	5 mg/mL
Solution / drops	Topical	5 mg/mL
Tablet	Oral	250 mg/1
Tablet	Oral	500 mg/1
Tablet	Oral	750 mg/1
Tablet, film coated	Oral	250 mg/1
Tablet, film coated	Oral	500 mg/1
Tablet, film coated	Oral	750 mg/1
Solution	Intravenous	5 mg
Tablet	Oral	250 mg
Tablet	Oral	500 mg
Solution	Respiratory (inhalation)	240 mg
Solution	Ophthalmic	5 mg/mL
Tablet	Oral	750 mg

Prices

Unit description	Cost	Unit
Iquix 1.5% Solution 5ml Bottle	81.68USD	bottle
Levofloxacin hemihydr 100% powder	42.69USD	g
Levaquin 750 mg tablet	28.06USD	each
Levaquin 750 mg leva-pak tablet	27.51USD	tablet
Levaquin 500 mg tablet	16.57USD	tablet
Iquix 1.5% eye drops	15.71USD	ml
Levaquin 250 mg tablet	13.71USD	tablet
Quixin 0.5% eye drops	12.21USD	ml
Quixin 0.5% Solution	11.4USD	ml
Levaquin i.v. 25 mg/ml vial	1.94USD	ml
Levaquin 500 mg/100 ml d5w	0.44USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5053407	No	1993-12-20	2010-12-20	US
US6806256	Yes	2002-08-26	2022-08-26	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Insoluble	Not Available
logP	2.1	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	1.44 mg/mL	ALOGPS
logP	-0.02	ALOGPS
logP	0.65	ChemAxon
logS	-2.4	ALOGPS
pKa (Strongest Acidic)	5.45	ChemAxon
pKa (Strongest Basic)	6.2	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	7	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	73.32 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	94.94 m³·mol^-1	ChemAxon
Polarizability	36.69 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)	splash10-00gm-1315975420-b0c4e6cdef799fda69b4	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)	splash10-0abc-3459425420-e8a4ecd2f8aea93fa660	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)	splash10-0h9p-3513893500-1d5c8069419fa2c37ebb	View in MoNA
1D NMR	1H NMR Spectrum	Not Available
2D NMR	[1H,13C] 2D NMR Spectrum	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Quinolines and derivatives

Sub Class

Quinoline carboxylic acids

Direct Parent

Quinoline carboxylic acids

Alternative Parents

Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Benzoxazines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines

Substituents

Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Benzoxazine / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

quinolone antibiotic, fluoroquinolone antibiotic, ofloxacin (CHEBI:63598 )

Targets

Details

1. DNA gyrase subunit A

Kind: Protein
Organism: Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action: yes
Actions: inhibitor

General Function:: Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:: DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:: gyrA
Uniprot ID:: P43700
Molecular Weight:: 97817.145 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779 ]
Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. [PubMed:10428935 ]
Messina C, Cafiso V, Campanile F, Santagati M, Stefani S: Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin. New Microbiol. 2001 Oct;24(4):347-53. [PubMed:11718372 ]

Details

2. DNA topoisomerase 4 subunit A

Kind: Protein
Organism: Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action: yes
Actions: inhibitor

General Function:: Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:: Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:: parC
Uniprot ID:: P43702
Molecular Weight:: 83366.24 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Zheng X, Johnson C, Lu Y, Yanagihara R, Hollingshead S, Crain M, Benjamin W Jr, Waites KB: Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes. Int J Antimicrob Agents. 2001 Oct;18(4):373-8. [PubMed:11691571 ]
Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29. [PubMed:17910998 ]
Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19. [PubMed:16857688 ]

Details

3. DNA topoisomerase 2-alpha

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Ubiquitin binding
Specific Function:: Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:: TOP2A
Uniprot ID:: P11388
Molecular Weight:: 174383.88 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. Cytochrome P450 1A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:: CYP1A2
Uniprot ID:: P05177
Molecular Weight:: 58293.76 Da

References

Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC: Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol. 2009 Oct;65(10):959-62. doi: 10.1007/s00228-009-0717-5. Epub 2009 Aug 26. [PubMed:19707748 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

2. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363 ]
Yamaguchi H, Yano I, Hashimoto Y, Inui KI: Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6. [PubMed:10992002 ]
Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316 ]

Details

2. Solute carrier family 22 member 6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:: SLC22A6
Uniprot ID:: Q4U2R8
Molecular Weight:: 61815.78 Da

References

Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570 ]

Details

3. Solute carrier family 22 member 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Quaternary ammonium group transmembrane transporter activity
Specific Function:: Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:: SLC22A2
Uniprot ID:: O15244
Molecular Weight:: 62579.99 Da

References

Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798 ]

Details

4. Solute carrier family 22 member 4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Symporter activity
Specific Function:: Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:: SLC22A4
Uniprot ID:: Q9H015
Molecular Weight:: 62154.48 Da

References

Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]

Drug created on June 13, 2005 07:24 / Updated on June 24, 2017 13:15

Get DrugBank to go!

Structure for DB01137 (Levofloxacin)

Targets

References

References

References

Enzymes

References

References

Transporters

References

References

References

References